Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Treasury Shares (2016 - 2025)

Amicus Therapeutics filings provide 1 years of Treasury Shares readings, the most recent being $71000.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 10.72% to $7.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 10.72% decrease, with the full-year FY2025 number at $7.4 million, down 10.72% from a year prior.
  • Treasury Shares hit $7.4 million in Q4 2025 for Amicus Therapeutics, down from $12.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $12.2 million in Q3 2025 to a low of $7390.0 in Q1 2025.
  • Median Treasury Shares over the past 5 years was $9.5 million (2024), compared with a mean of $8.2 million.
  • Biggest five-year swings in Treasury Shares: soared 32.37% in 2022 and later crashed 99.92% in 2025.
  • Amicus Therapeutics' Treasury Shares stood at $7.3 million in 2021, then skyrocketed by 32.37% to $9.7 million in 2022, then grew by 3.25% to $10.0 million in 2023, then fell by 17.5% to $8.3 million in 2024, then fell by 10.72% to $7.4 million in 2025.
  • The last three reported values for Treasury Shares were $71000.0 (Q4 2025), $71000.0 (Q3 2025), and $71000.0 (Q2 2025) per Business Quant data.